Entity Addresses, Address Type [Axis]
Business Contact [Member]
Class of Stock [Axis]
Common Class B [Member]
Equity Components [Axis]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Plan Name [Axis]
Standby Equity Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Liquidity And Going Concern [Member]
Cash and Cash Equivalents [Axis]
Money Market Funds [Member]
Antidilutive Securities [Axis]
Common Stock Warrants [Member]
Common Stock Options [Member]
Restricted Stock Units (RSUs) [Member]
Employees Stock Purchase Plan [Member]
Pre Paid Advance [Member]
Long-Lived Asset, Class [Axis]
Furniture Fixtures And Office Equipment [Member]
Statistical Measurement [Axis]
Minimum [Member]
Maximum [Member]
Laboratory Equipment [Member]
Leasehold Improvements [Member]
Nature of Expense [Axis]
Research And Development [Member]
General And Administrative [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Asset Class [Axis]
Cash and Cash Equivalents [Member]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
Warrant [Member]
Financial Instrument [Axis]
Pre Paid Advance Agreements [Member]
December 2024 [Member]
2020 Plan [Member]
Award Type [Axis]
Derivative Instrument [Axis]
Equity Option [Member]
December 2024 Offering [Member]
Common Stock Options And Restricted Stock Unit [Member]
Pre Paid Advance Agreement PPAs [Member]
Amended Bei Gene Collaboration [Member]
Context Therapeutics Inc [Member]
Related Party Transaction [Axis]
Himalaya Therapeutics SEZC [Member]
Related and Nonrelated Parties [Axis]
Inversagen LLC [Member]
Consolidation Items [Axis]
Operating Segments [Member]
Product and Service [Axis]
BA 3182 [Member]
Other CAB Programs [Member]
Total Program Expenses [Member]
Personnel And Related [Member]
Equity Based Compensation [Member]
Facilities And Other [Member]
BA 3011 [Member]
BA 3021[Member]
BA 3071 [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Counterparty Name [Axis]
Yorkville [Member]
Income Tax Jurisdiction [Axis]
U.S. Federal Statutory Income Tax Rate [Member]
Tax Credit Carryforward [Axis]
Research Tax Credit Carryforward [Member]
Entity Addresses [Table]
Entity Addresses [Line Items]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Contact Personnel Name
Statement [Table]
Statement [Line Items]
Assets
Current assets:
Cash and cash equivalents
Accounts receivable
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Operating lease right-of-use-asset, net
Other assets
Total assets
Liabilities and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable and accrued expenses
Operating lease liabilities
PPAs liability
Total current liabilities
Operating lease liabilities, less current portion
Liability to licensor
Warrant liability
Total liabilities
Commitments and contingencies (Note 6)
Stockholders’ equity (deficit):
Preferred stock, $0.0001 par value; 200,000,000 shares authorized at December 31, 2025 and December 31, 2024; 0 shares issued and outstanding at December 31, 2025 and December 31, 2024
Common stock value
Additional paid-in capital
Accumulated deficit
Total stockholders’ equity (deficit)
Total liabilities and stockholders’ equity (deficit)
Accounts payable and accrued expenses
Preferred stock, par value (in dollars per share)
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in dollars per share)
Common stock, authorized
Common stock, issued
Common stock, outstanding
Income Statement [Abstract]
Collaboration and other revenue
Operating expenses:
Research and development expense (includes related party amounts of $300 and $2,150 for the years ended December 31, 2025 and 2024, respectively)
General and administrative expense
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Gain on warrant liability
Loss on PPAs liability
Other expense
Total other income (expense)
Consolidated net loss and comprehensive loss
Net income (loss) per common share, basic
Net income (loss) per common share, diluted
Weighted-average shares of common stock outstanding, basic
Weighted-average shares of common stock outstanding, diluted
Research and development expense (includes related party amounts
Beginning balance, value
Beginning balance (in shares)
Issuance of common stock under equity incentive plans, net of shares withheld for taxes
Issuance of common stock under equity incentive plans, net of shares withheld for taxes (in shares)
Issuance of common stock for Employee Stock Purchase Plan
Issuance of common stock for Employee Stock Purchase Plan (in shares)
Taxes related to net share settlement of equity awards
Stock-based compensation expense
Net loss
Issuance of common stock under PPAs
Issuance of common stock under PPAs (in shares)
Issuance of common stock under SEPA
Issuance of common stock under SEPA (in shares)
Issuance of common stock, net of issuance costs and warrant liability
Issuance of common stock, net of issuance costs and warrant liability (in shares)
Issuance of common stock for commitment fee under SEPA
Issuance of common stock for commitment fee under SEPA (in shares)
Ending balance, value
Ending balance (in shares)
Statement of Cash Flows [Abstract]
Cash flows from operating activities
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Loss on disposal of property and equipment
Change in fair value of warrant liability
Change in fair value of PPAs liability
Commitment fee under SEPA
Financing costs related to PPAs
Change in fair value of PPAs
Stock-based compensation
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other assets
Accounts payable and accrued expenses
Accounts payable and accrued expenses - related parties
Right-of-use assets and lease liabilities, net
Net cash used in operating activities
Cash flows from financing activities
Proceeds from issuance of common stock under SEPA
Payment of financing costs related to issuance of common stock, PPAs and SEPA
Proceeds from issuance of common stock and warrants, net of issuance costs
Proceeds from issuance of common stock under Employee Stock Purchase Plan
Payments for taxes related to net settlement of equity awards
Proceeds from PPAs
Net cash provided by financing activities
Net decrease in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Supplemental disclosure of non-cash investing and financing activities
Fair value of common stock issued in satisfaction of PPAs liability
Increase in right-of-use assets and operating lease liabilities resulting from contract modification
PPAs related costs included in accounts payable and accrued expense
Equity issuance costs included in accounts payable and accrued expense
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies
Balance Sheet Details
Restructuring and Related Activities [Abstract]
Restructuring
Fair Value Disclosures [Abstract]
Fair Value Measurements
Leases
Leases
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Debt Disclosure [Abstract]
Pre-Paid Advance
Equity [Abstract]
Stockholders’ Equity
Collaboration License And Option Agreements
Collaboration, License and Option Agreements
Related Party Transactions [Abstract]
Related Party Transactions
Retirement Benefits [Abstract]
401(k) Plan
Segment Reporting [Abstract]
Segment Information
Subsequent Events [Abstract]
Subsequent Events
Income Tax Disclosure [Abstract]
Income Taxes
Organization
Merger and Related Share Consolidation
Basis of Presentation
Liquidity and Going Concern
Variable Interest Entities
Use of Estimates
Cash and Cash Equivalents
Stock-Based Compensation
Leases
Fair Value Option
Comprehensive Loss
Net Loss Per Share
Recent Accounting Pronouncements
Concentrations of Risk
Property and Equipment
Impairment of Long-Lived Assets
Derivative Instruments and Warrant Liabilities
Revenue Recognition
Research and Development Expenses
Patent Costs
Income Taxes
Schedule of basic and diluted net income loss per share
Schedule of anti-dilutive securities excluded from calculation of diluted net loss per share
Schedule of prepaid expenses other current assets
Schedule of property and equipment
Schedule of accounts payable and accrued expenses
Schedule of fair value assets and liabilities measured on recurring basis
Schedule of fair value, net derivative asset (liability) measured on recurring basis, unobservable input reconciliation
Schedule of changes in the fair value of warrant liability
Schedule of the changes in the fair value of PPAs liability
Components of lease expense
Summary of weighted average remaining lease term and weighted average discount rate
Supplemental cash flow information related to leases
Maturities of operating lease liabilities
Schedule of stock-based compensation expense
Summary of restricted stock units
Summary of stock option activity
Schedule of common stock reserved for future issuance
Schedule of assumptions used in Black-Scholes Model
Schedule of segment expenses reviewed by the CDMO
Effective Income Tax Rate Reconciliation [Table]
Effective Income Tax Rate Reconciliation [Line Items]
Schedule of unrecognized tax benefit amount
Schedule net deferred tax assets (liabilities)
Numerator:
Consolidated net income (loss)
Denominator:
Denominator for basic net income (loss) per share - weighted-average common stock outstanding
Effect of dilutive securities:
RSUs
Denominator for diluted net income (loss) per share - adjusted weighted-average common stock outstanding
Basic net income (loss) per share
Diluted net income (loss) per share
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted net loss per share
Prepaid research and development
Prepaid insurance
Other prepaid expenses and current assets
Total
Property, Plant, and Equipment [Table]
Property, Plant, and Equipment [Line Items]
Property, plant and equipment, gross
Property plant and equipment useful life
Less accumulated depreciation and amortization
Total
Accounts payable
Accrued research and development
Accrued research and development includes related party amount
Other accrued expenses
Total
Accrued compensation
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Company formation date
Number of shares sold under transaction
Proceeds from sale common of stock
Prepaid advance principal amount
Prepaid advance transaction price
Impairment losses
Pre Paid Advance in Fair Value
Accrued clinical trial cost
Interim Period, Costs Not Allocable [Table]
Interim Period, Costs Not Allocable [Line Items]
Reduction in workforce
Restructuring Cost
Cash payments
Restructuring liability
Fair Value, off-Balance-Sheet Risk [Table]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Cash equivalents
Warrants
Pre-Paid Advance
Liabilities
Common stock price
Risk-free rate
Expected term (in years)
Expected volatility
Dividend yield
Balance at December 31, 2024
Balance at December 31, 2025
Balance at December 31, 2024
Conversion of Pre-Paid Advance into common stock
Change in fair value of PPAs liability
Balance at December 31, 2025
Issuance of Pre-Paid Advance
Partial conversion of Pre-Paid Advance into common stock
Warrants excercise price
Components Of Lease Expense
Operating lease expense
Variable lease expense
Total lease expense, net
Summary Of Weighted Average Remaining Lease Term And Weighted Average Discount Rate
Weighted average remaining lease term (in years)
Weighted average discount rate percentage
Cash paid for amounts included in the measurement of operating leases
2026
2027
2028
2029
2030
Total future lease payments
Less imputed interest
Total operating lease liabilities
Operating lease right-of-use asset, net
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Aggregate principal amount
Purchase price discount
Gross proceeds to the Company
Interest rate
Unpaid deferred financing costs
Settlement of principal and accrued interest
Pre-Paid Advance Remaining Principal Amount
Maturity date
Default interest rate percentage
Prepayment premium
Purchase price per share
Lowest daily volume weighted average price
Percentage of outstanding common stock for exchange cap
Pre paid advance agreements amortization event, descripton
Pre-paid advance remaining principal amount
Advance fair value
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, Outstanding at beginning
Weighted - Average Grant Date Fair Value, beginning
Number of shares, Granted
Weighted - Average Grant Date Fair Value, Granted
Number of shares, Vested
Weighted - Average Grant Date Fair Value, Vested
Number of shares, Forfeited
Weighted - Average Grant Date Fair Value, Forfeited
Number of shares, Outstanding at ending
Weighted - Average Grant Date Fair Value, ending
Offsetting Assets [Table]
Offsetting Assets [Line Items]
Number of Options, Beginning balance
Weighted - Average Exercise Price Per Share, Beginning balance
Weighted - Average Remaining Contractual Term (In Years)
Aggregate Intrinsic Value, Beginning balance
Number of Options, Forfeited
Weighted - Average Exercise Price Per Share, Forfeited
Number of Options, Expired
Weighted - Average Exercise Price Per Share, Expired
Number of Options, Ending balance
Weighted - Average Exercise Price Per Share, Ending balance
Aggregate Intrinsic Value, Ending balance
Number of Options, Vested
Weighted - Average Exercise Price Per Share, Vested
Weighted - Average Remaining Contractual Term (In Years), Vested
Number of Options, Exercisable
Weighted - Average Exercise Price Per Share, Exercisable
Weighted - Average Remaining Contractual Term (In Years), Exercisable
Number of Options, Granted
Weighted - Average Exercise Price Per Share, Granted
Number of Options, Exercised
Weighted - Average Exercise Price Per Share, Exercised
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants for the purchase of common stock
Common stock options and restricted stock units issued and outstanding
Awards available for future issuance under the 2020 Plan
Awards available for future issuance under the ESPP
Shares available for future conversions of PPAs
Total common stock reserved for future issuance
Stock, Class of Stock [Table]
Class of Stock [Line Items]
Stockholders' Equity Note, Stock Split, Conversion Ratio
Percentage of average daily trading volume
Purchase common stock through payroll deductions of up to compensations, percent
Percentage of outstanding common stock
Common stock, shares issued (in shares)
Standby equity purchase agreement fees
SEPA Shares were sold
Standby equity purchase agreement fees
Common stock price
Purchase of common stock by warrants
Adjustment of warrants per share
Class of Warrant or Right, Outstanding and Exercisable
Percentage of Annual increased Shares
Vesting terms, description
Vesting percentage
Vesting period
Share-based payment arrangement, nonvested award, option, cost not yet recognized, amount
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition
Share-based compensation arrangement by share based payment award options grants in period weighted average grant date fair value
Fair value of options, vested
Common stock, shares authorized (in shares)
Share-based compensation arrangement by share based payment award percentage of outstanding stock maximum
Increase in issuance of common stock
Preferred stock, par value
Common stock par value per share
Conversion of stock, description
Period related to changing of ownership limitation percentage designated by Class B common stock holder
Common stock, voting rights
Percentage of outstanding common stock for exchange cap
Aggregate gross proceeds
Placement agent fees
Common shares authorized for issuance
Stock-based compensation expense
Upfront non-refundable payment.
Deferred Revenue, Current
Revenues
Maximum Potential Aggregate Payments
Amended license agreement first payable amount
Amended License Agreement Second Payable Amount
Collaboration Amendment Date
Related Party Transaction [Table]
Related Party Transaction [Line Items]
Description Of Agreement With Related Party
Research and Development Expense
Due to Related Party
Options Grants Related To Royalty Payments Period
Share of Royalties under Royalty Sharing Agreement
Defined Contribution Plan, Cost
Segment Reporting [Table]
Segment Reporting [Line Items]
Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer
General and Administrative Expense
Other Nonoperating Income (Expense)
Net Income (Loss) Attributable to Parent
Risk-free interest rate
Expected dividend yield
Expected term
Subsequent Event [Table]
Subsequent Event [Line Items]
Amended License Agreement Payment Received
Common Stock, Par or Stated Value Per Share
Sale Of Stock Maximum Commitment Amount
Commitment Fee Amount
Subsequent Event, Description
Outstanding pre paid advance amount convertible into common stock
Common Stock, Shares, Issued
Proceeds from Issuance of Common Stock
Reduction In Workforce
Tax computed at the federal statutory rate
Tax computed at the federal statutory rate, Percentage
State income taxes, net of federal tax benefit
State and local income taxes, net of federal income tax effect, Percentage
Research and development credit, Amount
Research and development credit, Percentage
Orphan drug credit, Amount
Orphan drug credit, Percentage
Valuation allowance
Change in valuation allowance, Percentage
Permanent items, Amount
Permanent items, Percentage
Nondeductible executive compensation
Equity compensation, Percentage
Nondeductible officers compensation, Amount
Nondeductible officers compensation, Percentage
Changes in unrecognized tax benefits, Amount
Changes in unrecognized tax benefits, Percentage
Other, net
Other, net, Percentage
Income tax expense
Provision for income taxes, Percentage
Stock-based compensation
Research and development and orphan drug credits
Uncertain tax positions
Net operating loss carryforwards
Liability to licensor
Goodwill
Lease liability
Accrued compensation
Research credit carryforwards
Section 174 cost capitalization
Section 59(e) cost capitalization
Stock-based compensation
Deferred gain
Fixed assets
Other
Gross deferred tax assets
Less: valuation allowance
Total deferred tax assets
Fixed assets
Operating lease right-of-use asset
Total deferred tax liabilities
Net deferred tax assets
Unrecognized tax benefits - beginning
Gross increases - tax positions in prior period
Gross increase - current-period tax positions
Unrecognized tax benefits - ending
Tax Credit Carryforward [Table]
Tax Credit Carryforward [Line Items]
Deferred Income Tax Expense (Benefit)
Income Tax Paid, before Refund Received
Deferred Tax Assets, Valuation Allowance
Change in Valuation Allowance
Federal Net Operating Loss Carryforward
State net operating loss carryforwards
Tax Credit Carryforward, Limitations on Use
Tax Credit Carryforward, Amount
Tax Credit Carryforward Expiration Period
Orphan Drug Credit
Orphan drug credit carryforwards Expiration Period
Use of annual operating loss carryforwards
The element represents paid advance agreement liability.
The element represents warrant liability.
The element represents gain loss on warrant liability.
The element represents gain loss on pre paid advance agreement liability.
The element represents taxes related to net share settlement of equity awards.
The element represents issuance of common stock under pre paid advance agreement shares.
The element represents issuance of common stock under standby equity purchase agreement shares.
The element represents issuance of common stock under standby equity purchase agreement value.
The element represents issuance of common stock under pre paid advance agreement value.
The element represents fair value of common stock related to pre paid advance agreement liabiliity.
The element represents increase in right of use assets and operating lease liabilities resulting from contract modification.
The element represents payments for taxes related to net settlement of equity awards1.
The element represents proceeds from issuance of common stock under stand by equity purchase agreement net.
The element represents change in fair value of pre paid advance agreement.
The element represents pre paid advance agreement liability.
The element represents issuance of common stock net of issuance costs and warrant liability shares.
The element represents issuance of common stock net of issuance costs and warrant liability.
The element represents issuance of common stock for commitment fee under standby equity purchase agreement shares.
The element represents issuance of common stock for commitment fee under standby equity purchase agreement value.
The element represents amended license agreement payment received.
The element represents context therapeutics inc member.
The element represents total program expenses member.
The element represents b a three one eight two member.
The element represents other c a b programs member.
The element represents personnel and related member.
The element represents equity based compensation member.
The element represents facilities and other member.
The element represents description of agreement with related party.
The element represents himalaya therapeutics sezc member.
The element represents due to related party.
The element represents collaboration license and option agreements text block.
The element represents collaboration agreement start date.
The element represents amended bei gene collaboration member.
The element represents upfront non refundable payment.
The element represents liability to licensor.
The element represents maximum potential aggregate payments.
The element represents amended license agreement second payable amount.
The element represents amended license agreement first payable amount.
The element represents percentage of average daily trading volume.
The element represents standby equity purchase agreement member.
The element represents percentage of outstanding common stock.
The element represents standby equity purchase agreement fees.
The element represents number of share sold.
The element represents december two thousand twenty four member.
The element represents class of warrant exercise price as adjusted.
The element represents class of warrant or right outstanding and exercisable.
The element represents percentage of annual increased shares.
The element represents two thousand twenty equity incentive plan member.
The element represents research and development expenses member.
The element represents employees stock purchase plan member.
The element represents schedule of common stock reserved for future issuance table text block.
The element represents warrant for the purchase of common stock.
The element represents common stock options and restricted stock unit member.
The element represents awards available for future issuance under the two thousand twenty plan.
The element represents pre paid advance agreement pp as member.
The element represents organization policy text block.
The element represents merger and related share consolidation policy text block.
The element represents liquidity and going concern policy text block.
The element represents company formation date.
The element represents liquidity and going concern member.
The element represents common stock warrants member.
The element represents common stock options member.
The element represents schedule of prepaid expenses other current assets table text block.
The element represents prepaid research and development expense.
The element represents other prepaid expenses and current assets.
The element represents furniture fixtures and office equipment member.
The element represents laboratory equipment member.
The element represents accrued research and development expense current.
The element represents accrued research and developments includes related party amount.
The element represents reduction in workforce.
The element represents fair value warrant liability.
The element represents pre paid advance.
The element represents schedule of the changes in the fair value of liabilities table text block.
The element represents partial conversion of pre paid advance into common stock.
The element represents change in fair value of pre paid advance.
The element represents common stock price per share.
The element represents pre paid advance agreements member.
The element represents debt instrument carrying amount percentage of face amount.
The element represents gross proceeds from pre paid advance agreements.
The element represents paid advance remaining principal amount.
The element represents schedule of the changes in the fair value of pp as liabilities table text block.
The element represents change in fair value of ppas liability.
The element represents proceeds from issuance of common stock and warrants net of issuance costs.
The element represents ppas related costs included in accounts payable and accrued expense.
The element represents equity issuance costs included in accounts payable and accrued expense.
The element represents proceeds from pre paid advance agreement.
The element represents financing costs related to pre paid advance agreement.
The element represents commitment fee under standby equity purchase agreement.
The element represents pre paid advance principal amount.
The element represents prepaid advance transaction price.
The element represents derivative instruments and warrant liabilities policy text block.
The element represents pre paid advance in fair value.
The element represents accrued research and development.
The element represents warrant liability member.
The element represents p p as liability member.
The element represents issuance of pre paid advance.
The element represents pre paid advance volume weighted average price percent.
The element represents pre paid advance agreements amortization event descripton.
The element represents pre paid advance remaining principal amount.
The element represents period related to changing of ownership limitation percentage designated by class b common stock holder.
The element represents class of stock axis.
The element represents percentage of outstanding common stock for exchange cap.
The element represents aggregate gross proceeds.
The element represents placement agent fees.
The element represents common shares authorized for issuance.
The element represents derivative instrument axis.
The element represents equity option member.
The element represents b a three zero one one member.
The element represents b a three zero two one member.
The element represents b a three zero seven one member.
The element represents effective income tax rate reconciliation tax credit orphan drug cedit amount.
The element represents effective income tax rate reconciliation tax credit orphan drug credit percent.
The element represents effective income tax rate reconciliation nondeductible expense permanent items amount.
The element represents effective income tax rate reconciliation nondeductible expense permanent items percent.
The element represents lease liability.
The element represents section174 cost capitalization.
The element represents section59 e cost capitalization.
The element represents deferred tax assets fixed assets.
The element represents federal net operating loss carryforward.
The element represents state net operating loss carryforwards.
The element represents research tax credit carryforward member.
The element represents tax credit carryforward expiration period.
The element represents orphan drug credit.
The element represents orphan drug credit carryforwards expiration period.
The element represents annual operating loss carryforwards use.
The element represents share of royalties under royalty sharing agreement.
The element represents options grants related to royalty payment period.
The element represents inversagen llc member.
The element represents himalaya member.
The element represents pre paid advance member.
The element represents research and development member.
The element represents general and administrative member.
The element represents december two thousand twenty four offering member.
The element represents share based compensation arrangement by share based payment award fair value assumptions expected term.
The element represents conversion of pre paid advance into common stock.
The element represents default rate percentage.
The element represents debt instrument prepayement premium percentange.
The element represents awards available for future issuance under the ESPP.
The element represents shares available for future conversions of PPAs.
The element represents sale of stock maximum commitment amount.
The element represents yorkville member.
The element represents commitment fee amount.
Assets, Current
Assets [Default Label]
Liabilities, Current
Liabilities [Default Label]
Equity, Attributable to Parent
Liabilities and Equity
Accounts Payable, Other, Current
Operating Expenses
Operating Income (Loss)
Other Expenses
Shares, Outstanding
Gain (Loss) on Disposition of Property Plant Equipment
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Proceeds From Issuance Of Common Stock Under Stand By Equity Purchase Agreement Net
Payments of Financing Costs
Payments For Taxes Related To Net Settlement Of Equity Awards One
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Lessee, Operating Leases [Text Block]
Lessee, Leases [Policy Text Block]
Income Tax, Policy [Policy Text Block]
Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization
Pre Paid Advance
Change In Fair Value Of Pre Paid Advance
Partial Conversion Of Pre Paid Advance Into Common Stock
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period
Sale of Stock, Price Per Share
Percentage Of Outstanding Common Stock For Exchange Cap
Employee Benefits and Share-Based Compensation
Share-Based Payment Arrangement, Expense, after Tax
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Bad Debt Reserve for Tax Purposes of Qualified Lender
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost
Deferred Tax Assets, Valuation Allowance
Deferred Tax Liabilities, Regulatory Assets
Deferred Tax Liabilities, Leasing Arrangements
Deferred Tax Liabilities, Net
Unrecognized Tax Benefits